Vysali Pharmaceuticals
In the Sep 2025 quarter, revenue was ₹37 Cr, against ₹36 Cr a year earlier and net profit was ₹7 Cr, against ₹6 Cr a year earlier (compared with Sep 2024). Promoters held 73.72% of Vysali Pharmaceuticals in Sep 2025, unchanged from Mar 2025.
Peer Comparison
Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
| ₹1,766.50 | 35.04 | 4,23,843 Cr | 5.07 | 0.91% | 13.79% | 17.94% | 61,848 Cr | 12,117 Cr | |
| ₹9,635.00 | 87.45 | 2,55,779 Cr | 15.26 | 0.32% | 15.32% | 18.96% | 11,682 Cr | 2,925 Cr | |
| ₹4,598.40 | 72.19 | 1,74,908 Cr | 9.52 | 0.82% | 12.16% | 9.06% | 17,058 Cr | 2,156 Cr | |
| ₹2,184.70 | 107.94 | 1,18,042 Cr | 22.27 | 0.09% | 16.38% | 19.67% | 7,323 Cr | 1,090 Cr | |
| ₹1,180.50 | 26.27 | 1,17,755 Cr | 4.34 | 0.09% | 16.99% | 19.24% | 28,515 Cr | 4,593 Cr | |
| ₹1,341.00 | 34.73 | 1,11,931 Cr | 2.88 | 0.61% | 10.87% | 13.94% | 34,247 Cr | 3,184 Cr | |
| ₹1,370.50 | 32.83 | 1,10,717 Cr | 3.13 | 0.96% | 11.21% | 14.88% | 28,589 Cr | 3,356 Cr | |
Vysali Pharmaceuticals (this company) | — | — | — | — | — | — | — | 105 Cr | 19 Cr |
| Median 8 companies | ₹1,766.50 | 35.04 | 1,18,042 Cr | 5.07 | 0.61% | 13.79% | 17.94% | 22,787 Cr | 3,055 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100. How it works →
No Tapetide Score has been computed for this stock yet.
Key Insights
Strengths
2- Company has reduced debt.
- Company's working capital requirements have reduced from 205 days to 147 days
Weaknesses
2- Company has low interest coverage ratio.
- Company might be capitalizing the interest cost
Growth Rate
change over 1 year
change over 1 year
Quarterly Results
| Particulars | Sep 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|
| Sales | 36 | 32 | 37 |
| Expenses | 29 | 25 | 30 |
| Operating Profit | 7 | 7 | 7 |
| OPM % | 19% | 21% | 20% |
| Other Income | 1 | 1 | 2 |
| Interest | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 |
| PBT | 8 | 8 | 9 |
| Tax % | 20% | 25% | 19% |
| Net Profit | 6 | 6 | 7 |
| EPS (₹) | 6.87 | 6.37 | 7.93 |
Profit & Loss
| Particulars | Mar 2006 | Jun 2007 15m |
|---|---|---|
| Sales | 5 | 10 |
| Expenses | 10 | 23 |
| Operating Profit | -5 | -13 |
| OPM % | -104% | -134% |
| Other Income | 1 | 26 |
| Interest | 0 | 0 |
| Depreciation | 0 | 0 |
| PBT | -5 | 12 |
| Tax % | 0% | 0% |
| Net Profit | -5 | 12 |
| Div. Payout % | 0% | 0% |
Balance Sheet
| Particulars | Mar 2006 | Jun 2007 |
|---|---|---|
| Equity Capital | 5 | 5 |
| Reserves | -19 | 6 |
| Borrowings | 21 | 10 |
| Other Liabilities | 5 | 5 |
| Total Liabilities | 12 | 27 |
| Fixed Assets | 4 | 17 |
| CWIP | 0 | 0 |
| Investments | 0 | 0 |
| Other Assets | 8 | 10 |
| Total Assets | 12 | 27 |
Cash Flow
| Particulars | Mar 2006 | Jun 2007 |
|---|---|---|
| Operating | — | 12 |
| Investing | — | 0 |
| Financing | — | -11 |
| Net Cash Flow | — | 1 |
| Free Cash Flow | — | 12 |
| CFO/OP | — | -93 |
Ratios
| Particulars | Mar 2006 | Jun 2007 |
|---|---|---|
| Debtor Days | 62 | 71 |
| Inventory Days | 565 | 377 |
| Days Payable | 130 | 108 |
| Cash Conversion Cycle | 497 | 340 |
| Working Capital Days | 263 | 147 |
| ROCE % | — | -2% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Vysali Pharmaceuticals insights
35 extracted metrics + investor summaries across FY06–FY26.
Documents
Frequently Asked Questions about Vysali Pharmaceuticals
Where is Vysali Pharmaceuticals Ltd (524290) listed?
Which sector does Vysali Pharmaceuticals Ltd belong to?
Company Information
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/524290.md for Vysali Pharmaceuticals Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.